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ABSTRACT
Purpose To develop a pharmacoepidemiologic method for drug utilization analysis according to indication, gender, and age by means of
register-based information. Statin utilization in 2005 was applied as an example.
Methods Following the recommendations for statin therapy, we constructed an indication hierarchy with eight mutually exclusive levels of
register markers of cardiovascular disease and diabetes. Danish residents, as of January 1, 1996, were followed at the individual level in
nationwide registers with respect to dispensed prescriptions of cardiovascular drugs and antidiabetics (1996–2005) along with discharge di-
agnoses and surgical procedures (1977–2005). The highest current possible indication level was assigned to all cohort members. Stratiﬁed by
indication, gender, and age, statin treatment prevalence and incidence were calculated.
Results Statin treatment prevalence was highest among individuals with myocardial infarction and tended to be higher among men with
indications in the upper part of the hierarchy, but it was higher among women (especially the elderly) in the lower part of the hierarchy.
Treatment incidence rates followed roughly the same pattern. Women with no register marker or primary hypertension accounted for almost
50% of all incident female users; among men, the ﬁgure was 35%. The proportion of incident users with ischemic heart disease or myocardial
infarction increased with age.
Conclusion The proposed indication hierarchy provided new insight into prescription patterns of statins. The method can be implemented
for other drug categories and could be useful for studying trends in drug utilization, differential drug adherence, and cross-national
comparisons. Copyright# 2011 John Wiley & Sons, Ltd.
key words—drug utilization; prescribing indication; indication hierarchy; pharmacoepidemiologic method; statins
Abbreviations: CVD, cardiovascular disease; MI, myocardial infarction; IHD, ischemic heart disease; PAD, peripheral arterial disease in the
lower limbs; PAC, potential atherosclerotic conditions; DNPR, Danish National Prescription Registry; ATC, Anatomical Therapeutic
Chemical classiﬁcation system; DDD, deﬁned daily dose
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BACKGROUND
During recent decades, the utilization of many drug
categories, such as lipid-lowering drugs, antihyper-
tensives, antidepressants, and bisphosphonates, has
increased dramatically. A major reason for this in-
crease could be the widening of indications for
prescribing, following the evidence of beneﬁcial
effects in patients other than those for which the drug
originally was intended. For example, the recommen-
dations for prescribing statins (HMG-CoA reductase
inhibitors) have broadened from hypercholesterolemia
among middle-aged men with myocardial infarction
(MI) to a preventive treatment for all individuals at
high risk of cardiovascular events regardless of lipid
levels 1–8 and irrespective of age and gender 9,10.
Although a range of studies from different countries
have explored trends in statin prescribing according to
age and gender, and some according to broad catego-
ries of underlying medical conditions 11–17, none have
applied a consistent pharmacoepidemiologic approach
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to analyze drug utilization according to indication.
Thus, it is unknown to what extent an indication creep
(i.e., the slow and silent widening of ofﬁcial and
unofﬁcial indications, leading to expanding consump-
tion) affects age- and gender-speciﬁc drug treatment
prevalence and incidence. Knowledge of actual
patterns of drug utilization according to indication
could help to explain drivers behind the growing drug
use. It could also determine to what extent a particular
drug is used for its main indication, where the beneﬁ-
cial effect normally is highest and the adverse effect-
to-beneﬁt ratio presumably is at its lowest.
The nationwide individual-level registries in Denmark
include a range of health care and sociodemographic
information, representing a unique data source for drug
utilization analysis 18,19. Using the prescription regis-
try, we previously developed a pharmacoepidemiolo-
gic semi-Markov model for analyzing the dynamics
behind the increasing prevalence of treatment with
cardiovascular drugs 20. By means of the model, we
demonstrated that population aging accounted for
about 7% of the growth in treatment prevalence with
statins during 1996–2005, whereas increasing treat-
ment incidence accounted for 72%. It is likely that part
of the latter increase is explained by a widening of
indications and changing prescribing behavior.
However, the prescription data contain no structured
information about indication. Instead, discharge diag-
noses combined with dispensing information for
certain drugs may serve as markers of medical condi-
tions present at speciﬁc points in time. These register
markers can be applied as a proxy for the indication
if identifying diagnoses and medication that corre-
spond to the recommended indications for prescribing
a particular drug.
The aim of the present study was to develop a phar-
macoepidemiologic method to analyze drug utilization
according to indication, age, gender, and calendar
year, applying a hierarchy of register markers for
recommended prescribing indications. We demon-
strate the method with statin utilization as an example.
MATERIAL AND METHODS
The indications for statin therapy cover the range of
medical conditions for which lipid-lowering therapy
can be recommended based on scientiﬁc evidence.
Thus, we reviewed the most important randomized
placebo-controlled trials on the beneﬁcial effect of
statins (i.e., reduced cardiovascular morbidity and
mortality) 1,3–10 and the regularly updated European
and Danish national guidelines for prevention of
cardiovascular disease (CVD) 21–29.
Irrespective of age and gender, statins are now recom-
mended for individuals with established atherosclerotic
CVD: individuals with MI, ischemic heart disease
(IHD), stroke, and atherosclerotic CVD in general, but
especially peripheral arterial disease in the lower
limbs (PAD) 25. In addition, statins are recommended
for individuals without established CVD, but who are
at high risk of CVD, such as individuals with diabetes,
asymptomatic individuals with hypertension, or indi-
viduals with other risk factors for CVD (i.e.,
hypercholesterolemia). Preventive drug therapy (sta-
tins and/or antihypertensives) is now recommended
for asymptomatic individuals with a 10-year risk of a
fatal CVD above 5%, estimated by means of, for ex-
ample, the European Systematic Coronary Risk Evalu-
ation 30. Statins are a priori recommended for
individuals with a familial disposition for CVD, such
as familial hypercholesterolemia 22,23,27,28.
Corresponding to the priorities described in guide-
lines, we constructed a statin indication hierarchy:
MI, IHD, stroke, PAD, other potential atherosclerotic
conditions (PAC), diabetes, primary hypertension,
and a group with no markers of diagnosis (Table 1).
The statin indication for a person with several quali-
fying medical conditions was assumed to be the
one at the highest level. Individual-level register
information on discharge diagnoses, invasive proce-
dures, and information on drug dispensing were
applied as markers of disease prior to initiation of
statin therapy.
From three nationwide registers maintained by
Statistics Denmark and The National Board of Health,
we retrieved historical data on demographics,
dispensed cardiovascular drugs (1995–2005), and
inpatient–outpatient information (1977–2005). Records
at the individual level were linked by means of a unique
encrypted person identiﬁer 31. The linkage allows
authorized researchers to follow individuals in multi-
ple individual-level registries hosted in Statistics
Denmark through secured Internet access.
All Danish residents, as of January 1, 1996, were
identiﬁed in the demographic registry (N=5,114,040)
and followed until December 31, 2005. The registry
contains information on gender, year of birth, and date
of death or emigration. To categorize cohort members
as incident or prevalent drug users, we used a 1-year
run-in period 32, and accordingly, persons not fully
observable during 1995 were excluded. Furthermore,
to avoid misclassiﬁcation of disease history, people
who immigrated within 10years before the observa-
tion period were excluded, resulting in a ﬁnal cohort
of 4,998,578 members. Analyses were each year lim-
ited to individuals older than 20years.
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The Danish National Prescription Registry (DNPR)
contains full information since 1995 on all out-of-
hospital purchases of prescription drugs at Danish
pharmacies, including prescriptions for nursing home
residents 19. Records include the person identiﬁer, date
of dispensing, the Anatomical Therapeutic Chemical
(ATC) classiﬁcation code of the dispensed drug 33,
and the amount in deﬁned daily doses (DDDs). The
records do not contain information on prescribed dose
or on the indication. From the DNPR, we retrieved in-
formation on dispensed cardiovascular drugs (ATC
groups C and B01) and antidiabetics (A10).
The Danish National Patient Registry contains infor-
mation on all patients discharged from non-psychiatric
hospitals since 1977. Records include the admission
and discharge dates, discharge diagnoses according to
the International Classiﬁcation of Diseases (ICD), 8th
revision until 1993 and 10th revision thereafter 34,
along with codes for diagnostic and surgical proce-
dures. We included both primary and secondary
diagnoses for admitted patients (discharge date) and
patients in ambulant care (admission date) but did
not include emergency room visits.
Each cohort member was assigned to the highest
possible level in the indication hierarchy corre-
sponding to current diagnosis or drug register markers
(Table 1). The ﬁrst date with a register marker of one
of the cardiovascular conditions deﬁnes an individual's
transition into the corresponding indication level. For
example, regardless of any other register markers,
individuals with prior MI will be assigned to the high-
est level, i.e. MI is assumed to be the indication for
initiating statin therapy. The IHD level is assigned to
individuals without MI, but with either hospital or
drug markers indicating IHD (Table 1). Two consecu-
tive dispensing of nitrates (C01DA) or one dispensing
of nitrates followed by dispensing of aspirin (acetylsa-
licylic acid, B01AC06) during a 12-month period were
regarded as drug markers of IHD 12,35,36. To avoid im-
mortal time bias, the last of the two dispensing dates
was applied as the IHD transition date. The levels
corresponding to stroke or PAD were used only when
higher level markers were not present.
Potential atherosclerotic conditions were deﬁned as
a range of cardiovascular conditions such as heart fail-
ure, secondary hypertension, arteriosclerosis of the
aorta, renal or intestinal arteries or upper limbs, certain
mitral valve disorders (i.e., nonrheumatic, noninfec-
tious, and noncongenital), and arrhythmias. At this
level, we also included drug markers (digitalis glyco-
sides and loop diuretics). For diabetes, we included
as markers both dispensed antidiabetics and diabetes
diagnoses. As markers for primary hypertension, we
applied all potential antihypertensive drugs, the most
important groups being beta-blockers, thiazide diuret-
ics, calcium channel blockers, ACE inhibitors, and
angiotensin II receptor antagonists. While individuals
were categorized as having primary hypertension after
the ﬁrst dispensing of an antihypertensive - provided
no markers of higher CVD levels, no diagnosis was
assigned to individuals without any of the applied
register markers. Individuals at these two lower
levels in the hierarchy are referred to as asymptomatic
individuals.
The dataset for pharmacoepidemiologic analyses
was created by combining individual-level informa-
tion as to statin dispensing dates with the time
sequence of indication transitions. By this means,
indication-speciﬁc person–time at risk of initiating or
discontinuing statin therapy can be calculated.
Prevalent statin users were deﬁned as individuals
who by January 1 (index date) had purchased a statin
prescription at least once during the preceding 365
days. Incident statin users were deﬁned as non-users
with the ﬁrst statin dispensing between the index date
and the next 365days. While the indication for initiat-
ing statin therapy was assumed to correspond to the
indication level at the date of ﬁrst dispensing, the indi-
cation for continued statin treatment among prevalent
users was assumed to correspond to the level attained
in the hierarchy as of the index date of the current year.
Thus, the indication could change after the therapy
was initiated.
The treatment prevalence proportion was calculated
as the number of prevalent statin users at the beginning
of a calendar year relative to the total number of indi-
viduals at that time. The treatment incidence rate was
calculated as the number of incident statin users during
a year relative to person–time at risk (censoring at
death, emigration, or transition to a higher indication
level). We calculated these measures both overall and
stratiﬁed by calendar year, indication, gender, and
age groups.
All analyses were performed using Stata Release
11.1 (StataCorp, College Station, TX, USA). Access
to data was provided and secured through collabora-
tion between the University of Copenhagen and Sta-
tistics Denmark. Register-based studies in Denmark
do not require approval by an ethics board.
RESULTS
As an illustration of the method, we present statin
treatment prevalence and incidence as of 2005, accord-
ing to indication, gender, and age.
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Table 2 indicates that the overall statin treatment
prevalence was 62/1000 inhabitants (aged 20+ years),
corresponding to 237,336 prevalent users. Treatment
prevalence was generally higher among men than
women (69/1000 vs. 56/1000), with the age-speciﬁc
treatment prevalence peaking for both genders at the
age of 65–74 years. The relative gender difference
was most pronounced at younger ages. Whereas
women aged 75+ years accounted for 22.7% of the fe-
male statin users, the same ﬁgure was 15.8% among
male users.
Treatment prevalence was highest among indivi-
duals with MI (649/1000 v. 563/1000 in men and
women, respectively) and tended to be higher among
men with indications in the upper part of the hierarchy,
but it was higher among women (especially the older
persons) in the lower part of the hierarchy. Whereas
MI patients accounted for 29.2% of the male statin
users, the ﬁgure was 14.2% among women. For pri-
mary hypertension, in contrast, the ﬁgures were
12.4% and 21.1% respectively.
The pattern of treatment incidence (Table 3) follows
roughly that of treatment prevalence. The highest inci-
dence rate is found among individuals with MI, fol-
lowed by diabetes, stroke, PAD, and IHD. While the
incidence of statin therapy in patients with MI and
IHD is highest among men, the opposite is the case
in elderly with diabetes, hypertension and those with
no diagnosis. Incidence generally decreases above
the age of 75 years.
Table 3. Incidence of statin use in Denmark during 2005: treatment incidence according to indication, gender, and age
Gender Age,
years
Treatment incidence (per 1000 person-years at risk) according to indication*, gender, and age
MI IHD Stroke PAD PAC Diabetes Hypertension No diagnosis
20–39 260 36 55 21 20 62 9 1
40–54 467 101 155 92 48 166 40 5
Male 55–64 429 135 190 137 68 194 56 10
65–74 357 136 170 134 65 180 57 11
75–84 209 90 106 91 35 114 30 7
+85 87 27 43 27 11 34 9 1
20–39 191 32 38 8 8 36 2 1
40–54 334 77 114 76 27 122 19 3
Female 55–64 338 107 154 129 53 225 50 12
65–74 343 115 174 142 59 223 61 17
75–84 214 74 107 97 37 131 36 11
+85 73 20 32 29 7 39 8 3
*See Table 1 for deﬁnitions and abbreviations.
Table 2. Statin treatment prevalence according to indication, gender, and age: number of prevalent statin users and statin treatment prevalence by January 1, 2005
Gender Age,
years
N (%)* Treatment prevalence (per 1000 persons) according to indication†, gender, and age
All MI IHD Stroke PAD PAC Diabetes Hypertension Risk
20–39 2,390 (1.9) 4 548 142 95 66 25 101 15 1
40–54 23,190 (18.0) 43 751 354 309 310 102 307 77 10
55–64 43,458 (33.7) 126 760 480 373 357 158 390 116 20
Male 65–74 39,391 (30.6) 196 711 481 346 339 155 370 112 24
75–84 18,963 (14.7) 169 531 309 202 216 79 260 60 13
+85 1,384 (1.1) 48 194 60 57 60 13 48 13 2
All* 128,776 69 649 (29.2) 386 (19.9) 285 (9.3) 296 (2.5) 111 (7.4) 312 (10.2) 86 (12.4) 9 (9.1)
20–39 1,520 (1.4) 3 490 104 88 64 17 62 4 1
40–54 13,840 (12.7) 26 709 274 238 306 57 246 34 6
55–64 32,469 (29.9) 93 737 393 377 404 129 439 97 23
Female 65–74 36,196 (33.3) 161 720 426 370 392 159 450 130 36
75–84 22,113 (20.4) 134 538 257 220 262 89 301 74 20
+85 2,488 (2.3) 35 167 48 59 72 15 64 13 3
All* 108,590 56 562 (14.2) 281 (17.8) 252 (9.9) 310 (3.3) 91 (13.2) 301 (9.9) 66 (21.1) 9 (10.6)
Both All* 237,366 62 621 (22.3) 332 (19.0) 269 (9.6) 303 (2.9) 98 (10.0) 307 (10.1) 73 (16.4) 9 (9.8)
*The distribution (%) of prevalent statin users according to age or indication.
†See Table 1 for deﬁnitions and abbreviations.
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Figure 1 depicts the percentage distribution accord-
ing to indication among incident statin users during
2005. Among women, primary hypertension is the
most frequent indication. Almost 50% of all incident
female users are asymptomatic (hypertension or no di-
agnosis), whereas MI accounted for less than 10%.
Among men, asymptomatic individuals accounted for
35%; MI, for 15%.
Figure 2 shows the percentage distribution of
incident statin users according to age and indication -
stratiﬁed by gender. For both genders, the share of inci-
dent users with indications at the highest level of the
hierarchy increased with age, and for all age groups,
this share was highest among men. The two indications
highest in the hierarchy (MI and IHD) accounted for
28% of incident prescribing among men aged 55–64
years and 14% among women. The corresponding
shares were 50% and 35% among individuals aged
75–84 years. Conversely, the two indications lowest
in the hierarchy (no diagnosis and hypertension)
accounted for 40% of incident prescribing among
men aged 55–64 years and 55% among women. Among
individuals aged 75–84 years, the corresponding shares
were 15% and 28%.
DISCUSSION
Method and principal ﬁndings
Applying register-based information, we developed a
pharmacoepidemiologic method for drug utilization
analyses according to indication, gender, and age.
The method is based on a hierarchy of mutually exclu-
sive indications and allows for in-depth drug utiliza-
tion analyses of treatment prevalence and incidence
according to indication.
Analyses of statin utilization in 2005 revealed that
treatment prevalence was highest among individuals with
MI and tended to be higher among men with indications
in the upper part of the hierarchy, but it was higher
among women (especially the elderly) in the lower part
of the hierarchy. Treatment incidence rates followed
roughly the same pattern. The share of incident users in
the upper part of the hierarchy increased with age.
Strengths and limitations
Because guidelines are applied as clinical prescribing
recommendations, we consider it a strength that our in-
dication hierarchy is based on the recommendations
described in the guidelines. The hierarchy implicitly
prioritizes among indications such that the indication
for statin therapy for an individual with MI will be
Figure 1. Number of incident statin users by gender during 2005: percent-
age distribution according to indication. Cf. Table 1 for abbreviations of the
diagnoses in the indication hierarchy
Figure 2. Number of incident statin users during 2005 stratiﬁed by gen-
der. Percentage distribution according to age and indication. Cf. Table 1
for abbreviations of the diagnoses in the indication hierarchy
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MI—irrespective of eventual subsequent conditions
that might have triggered the prescribing. Alterna-
tively, we could have applied an approach where
the indication level was determined by a combina-
tion of all CVD markers and risk factors. Although
this is likely to be too complex for exploring drug
utilization patterns, it may be fruitful in multivariate
analyses of treatment in different patient groups
according to co-morbidity.
The challenge was to identify credible register mar-
kers for the conditions reﬂecting the recommended
statin indications. By systematically identifying all po-
tential register markers (in-hospital and drug markers),
we were able to establish a hierarchy of eight mutually
exclusive indication groups, including a gray-zone
group with PAC and a no diagnosis group. Without
the gray-zone group, subjects with more-or-less obvious
atherosclerotic conditions would have been misclassi-
ﬁed downward in the hierarchy—eventually to the no
diagnosis group. Owing to the strong evidence for statin
therapy among individuals with PAD 25, we opted to re-
strict this subgroup to PAD only—leaving, for example,
aorta aneurism in the gray-zone group.
The main limitation of the study is the lack
of information on familial hypercholesterolemia,
microalbuminuria (statin indication criterion for Type
I diabetics), and low ankle blood pressure (indicating
PAD). Consequently, CVD-free statin users among
the approximately 10,000 individuals with familial
hypercholesterolemia in Denmark 37 are classiﬁed as
having no diagnosis. We also opted not to distinguish
between Type I and Type II diabetes.
To reduce the risk of misclassiﬁcation, we traced
hospital information on CVD since the beginning
of registration in 1977. This is a strength of this
study, representing a considerably longer period
of observation than that applied in similar studies
11–13. We evaluated the impact of applying shorter di-
agnosis run-in periods to capture surviving individuals
with prior MI by means of registered hospital MI diag-
noses. Although only 60% of the MI patients would be
captured applying a run-in period of 3years, 74% and
94% would be captured with run-in periods of 5 and
10years, respectively. With a run-in period of 3years,
the distribution of incident statin users, shown in
Figure 1, would shift towards “lighter” diagnoses:
about seven percentage points fewer statin-users
would be categorized as initiating therapy on MI/
IHD indication, and a higher percentage would belong
to the hypertension and PAC categories. We thus
applied a diagnosis run-in window of at least 10years
for immigrants to minimize the bias introduced when
comparing statin indication over time.
In line with a study from British Columbia 13, we
found a tendency for relatively high treatment preva-
lence among women and the older persons “without
heart disease”—applying their rather broad categories.
However, our analysis demonstrates a more nuanced
picture. In contrast to a study from Ireland exclusively
using dispensing information as disease markers 12, we
applied both in-hospital and dispensing information as
register markers, making it possible to distinguish
between primary and secondary hypertension. Further-
more, drug information was in our study applied to
identify patients exclusively treated in primary care.
To categorize an individual as an IHD patient, we
required two consecutive dispensings of nitrates
(or nitrate followed by aspirin), applying the last of
the two dates as the transition date to IHD to avoid
immortal time bias. Yet, this may lead to misclassiﬁca-
tion of some incident users. As this presumably small
group will be correctly categorized as prevalent
users the following year, we consider this latter bias
less serious.
Antihypertensives may also be used for other
indications, for example, ACE inhibitors and angio-
tensin II antagonists for heart failure, beta-blockers,
and calcium channel blockers for angina pectoris or
supraventricular tachycardia. These indications
belong to the IHD or PAC categories, but we
assume that the majority of heart patients (not
kidney patients) would be captured by inpatient or
outpatient diagnoses. Thus, we used thiazides as
markers of primary hypertension and loop diuretics
as markers of PAC, which corresponds to Danish
guidelines recommending loop diuretics in hyper-
tension patients with heart failure or nephropathy
but not in uncomplicated hypertension. Users of
beta-blockers for migraine or thiazides for edema,
however, may be misclassiﬁed as having hyperten-
sion. Thus, further validation of the drug markers
for hypertension based on information from primary
care is needed.
The stringent pharmacoepidemiologic approach
enabled us to calculate the precise number of statin
users and the corresponding denominators, stratiﬁed
by indication. This allows for unbiased calculations
of treatment incidence and prevalence. Raymond and
colleagues applied a register-based statin indication
hierarchy 11-similar to ours as to the medical condi-
tions, but not regarding the pharmacoepidemiologic
measures. Applying the whole population as denomi-
nator, incidence and prevalence according to indica-
tion tend to be underestimated and time trends will
be hard to detect. Without day-to-day information
about new CVD diagnoses, incident statin users with
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a recent CVD diagnosis will be classiﬁed corres-
ponding to the diagnosis level as of the index date
(e.g., January 1).
Applications of the method
The person–time applied for calculations of incidence
rate can also be used to estimate treatment discon-
tinuation rates according to indication, deﬁning for
instance discontinuation as 365 days since last pre-
scription 20. As adherence (persistence) to therapy is
an important aspect of drug treatment 38, the method
also applies for measuring adherence according to
indication. In addition, the method can be used to
consider the epidemiology of the disease, that is, the
incidence and prevalence of diseases in the hierarchy,
and thus also to calculate the proportion of never-
treated patients.
The indication hierarchy may be elaborated for
other drug categories (e.g., antidepressants and bis-
phosphonates) to study a potential indication creep.
A hierarchy for antidepressants could be based on
psychiatric discharge diagnoses, co-morbidities, and
prescriber categories (specialist or general practi-
tioner). For bisphosphonates, the hierarchy could be
based on indication markers such as osteoporosis-
related fractures, bone mineral density scans, treatment
with systemic corticosteroids, bone metastases, and
so forth.
Postmarketing surveillance studies tend to focus
on potential adverse effects without assessing a risk-
to-beneﬁt trade-off, which is likely to depend on
the indication. Analyses combining the indication
hierarchy and a risk-to-beneﬁt ratio may help to make
treatment recommendations more speciﬁc. This could
be done both for drugs used symptomatically with
potentially life-threatening adverse effects, like COX-
2 inhibitors, and for preventive drugs, such as statins,
with less severe adverse effects. In the former case,
diagnoses of rheumatic diseases and other conditions
with chronic pain could be combined with markers
of the risk of adverse effects, for example, previous
peptic ulcers.
Cost-effectiveness analyses of drug therapies are
increasingly applied in decision making, but the result
depends to a large extent on actual indication patterns
and adherence to therapy. The number of prevalent
users, the volume of use in DDDs, and drug expendi-
tures could be analyzed using the indication hierarchy,
shedding light on cost-effectiveness in clinical prac-
tice. Finally, we believe that the method will be useful
in cross-national comparisons of drug utilization.
Conclusion
The proposed indication hierarchy provided insight
into prescription indication patterns as to statin
utilization in 2005. The method can be imple-
mented for other drug categories and is consid-
ered useful for studying trends in drug utilization,
differential drug adherence, and cross-national
comparisons.
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KEY POINTS
• The utilization of many drug categories has
increased dramatically during the last decades,
posing an increasing burden on health care
resources. Yet, it is unknown to what extent the
increasing utilization is due to changing prescribing
indications—or an indication creep.
• We developed a pharmacoepidemiologic method
to analyze drug utilization according to indica-
tion, age, gender, and calendar year. Applying a
hierarchy of register-based markers of recom-
mended prescribing indications, the method was
demonstrated on statin utilization in 2005.
• The analysis revealed that statin treatment pre-
valence and incidence tended to be higher
among men with indications in the upper part
of the hierarchy (MI or IHD), but it was higher
among women in the lower part of the hierar-
chy (primary hypertension or no-register-based
diagnosis).
• Although the actual indication hierarchy will be
useful for studying trends in statin utilization
and statin adherence, the method could also be
adapted to other drug categories.
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